MANNKIND CORP Proceeds from Sale of Intangible Assets
MANNKIND CORP (MNKD) reported Proceeds from Sale of Intangible Assets of $9.25 million for the 9-month period ending 2014-09-30, per its 10-Q filed 2015-11-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfIntangibleAssets · last filed 2015-11-09
- 2014-09-30: Proceeds from Sale of Intangible Assets 9 month $9.25M.
| Period end | Proceeds from Sale of Intangible Assets 9 month |
|---|---|
| 2014-09-30 | $9.25M 10-Q · filed 2015-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |